CRBP CORBUS PHARMACEUTICA

10.35
+1  (8%)
Previous Close 9.60
Open 9.75
Price To book 48.00
Market Cap 504.06M
Shares 48,701,000
Volume 2,724,309
Short Ratio 5.34
Av. Daily Volume 841,270

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due by the end of March 2017.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 trial to be initiated 2Q 2017.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 2 data due 3Q 2017.
Anabasum (Resunab)
Dermatomyositis
Phase 2 data released November 14, 2016.
Anabasum (Resunab)
Systemic Sclerosis

Latest News

  1. 3 Stocks at 52-Week Highs Still Worth Buying
  2. Corbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  3. Inside the small Norwood biotech that's making investors swoon
  4. Corbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  5. CORBUS PHARMACEUTICALS HOLDINGS, INC. Financials
  6. 3 Biotech Stock Rockets With More Fuel in the Tank
  7. CORBUS PHARMACEUTICALS HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  8. CORBUS PHARMACEUTICALS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation F
  9. Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
  10. Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
  11. CORBUS PHARMACEUTICALS HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  12. Biotech Bounce Set to Pick Up Steam
  13. Marijuana Stocks Are Doomed if Trump Reneges on His Pot Pledge
  14. Corbus Pharmaceuticals Completes $27.2 Million Registered Direct Offering
  15. Corbus Pharmaceuticals Holdings Inc (CRBP) Share Offering Hints At $7 Floor With Threatening Short Squeeze
  16. Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
  17. CORBUS PHARMACEUTICALS HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD D
  18. Corbus Pharmaceuticals Announces $27.2 Million Registered Direct Offering
  19. Institutional Investors Continue to Pour Into Corbus Pharmaceuticals
  20. Can This Marijuana Stock Add Some Green to Your Portfolio? A Closer Look at Corbus Pharmaceuticals